Home > Clinical Resources > Guidance >
First published on 26 Aug 2015
Vedolizumab (Entyvio) is recommended. It is a possible option for adults with moderate to severe Crohn’s disease if a tumour necrosis factor (TNF)-alpha inhibitor isn’t suitable or hasn’t worked well enough. People should be able to have vedolizumab until it […]
First published on 22 Jul 2015
Naloxegol is recommended, within its marketing authorisation, as an option for treating opioid induced constipation in adults whose constipation has not adequately responded to laxatives. An inadequate response is defined as opioid-induced constipation symptoms of at least moderate severity in […]
First published on 05 Jun 2015
June 2015 Vedolizumab (Entyvio) is recommended by NICE as a possible treatment for adults with moderate to severe ulcerative colitis. People should be able to have the treatment until it stops working or surgery is needed. Their condition should be […]
First published on 25 Feb 2015
February 2015 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) Infliximab (also known as Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) […]
First published on 01 Jul 2014
Misc authors July 2014 A new report from Jervoise Andreyev and his team at the Marsden was published as an open access article in Frontline Gastroenterology and can be found via the link below. Macmillan funded the design and print […]
First published on 01 Jun 2014
Author Mark Wilkinson, (BSG Endoscopy, working party convenor and chairman) et al. June 2014 Executive Summary To improve the quality and availability of ERCP in the UK, a working party was set up incorporating a number of stakeholders (Appendix 3) to […]
First published on 01 Oct 2013
Faecal calprotectin testing is recommended as an option to support clinicians with the differential diagnosis of inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS) in adults with recent onset lower gastrointestinal symptoms for whom specialist assessment is being considered, […]
First published on 04 Nov 2011
The number of patients with chronic gastrointestinal (GI) symptoms after cancer therapies which have a moderate or severe impact on quality of life is similar to the number diagnosed with inflammatory bowel disease annually. However, in contrast to patients with […]